Table 3.
Variable | Univariate analyses HR (95% CI) | P-value | Multivariate analyses HR (95% CI) | P-value |
---|---|---|---|---|
| ||||
Age | ||||
≤65 years | 1 | 0.01 | – | – |
>65 years | 1.958 (1.175–3.354) | |||
BMI | ||||
<24 | 1 | 0.277 | ||
≥24 | 0.747 (0.442–1.264) | |||
Gender | ||||
Male | 1 | 0.504 | ||
Female | 0.764 (0.347–1.681) | |||
Smoking history | ||||
No | 1 | <0.001 | 1 | <0.001 |
Yes | 5.046 (2.800–9.093) | 4.169 (2.218–7.835) | ||
Hypertension | ||||
No | 1 | 0.323 | ||
Yes | 1.365 (0.736–2.531) | |||
Diabetes mellitus | ||||
No | 1 | 0.702 | ||
Yes | 1.118 (0.632–1.978) | |||
Cardiovascular disease | ||||
No | 1 | 0.542 | ||
Yes | 0.851 (0.507–1.429) | |||
Histology type | ||||
Transitional cell carcinoma | 0.44 | |||
Non-transitional cell carcinoma | 1.295 (0.673–2.492) | |||
Grade | ||||
1 and 2 | 1 | 0.295 | ||
3 | 1.569 (0.675–3.647) | |||
T-stage | ||||
NMIBC | 1 | <0.001 | 1 | 0.001 |
MIBC | 6.084 (2.983–12.408) | 3.361 (1.601–7.055) | ||
N-stage | ||||
Negative | 1 | 0.018 | – | – |
Positive | 2.221 (1.147–4.301) | |||
M-stage | ||||
Negative | 1 | 0.018 | 1 | 0.006 |
Positive | 3.035 (1.208–7.625) | 4.006 (1.494–10.742) | ||
ASA grade | ||||
1 and 2 | 1 | 0.013 | – | – |
3 and 4 | 2.385 (1.204–4.724) | |||
NLR | ||||
≤3.8 | 1 | <0.001 | – | – |
>3.8 | 2.754 (1.655–4.584) | |||
PLR | ||||
≤210.9 | 1 | 0.01 | – | – |
>210.9 | 2.248 (1.212–4.167) | |||
PNI | ||||
≤38.5 | 1 | 0.002 | – | – |
>38.5 | 0.380 (0.208–0.692) | |||
CAR | ||||
≤0.2 | 1 | <0.001 | 1 | <0.001 |
>0.2 | 4.214 (2.500–7.102) | 3.063 (1.788–5.249) |
Note: P-values <0.05 are shown in bold.
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CAR, C-reactive protein/albumin ratio; MIBC, muscle-invasive bladder cancer; NLR, neutrophil-to-lymphocyte ratio; NMIBC, non-muscle invasive bladder cancer; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index.